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Abstract Proximal Roux-en Y gastric bypass (RYGB) rep-
resenting the most frequently performed bariatric procedure
yields a weight loss failure rate of around 20 %. In order to
reduce failure rates, we established a novel distal RYGB
variant characterized by a very long alimentary (Roux) limb
and a short common channel. Up to 5 years, follow-up data
(complication rates, weight loss, nutritional/metabolic
changes) of the first 355 patients (mean±SD preoperative
age, 41.4±10.8 years; BMI, 48.5±11.5 kg/m2) who under-
went the novel Distal Very Long Roux-en Y Gastric Bypass
(DVLRYGB) were analysed. Overall follow-up rate was
98.9 %, mean follow-up time 1.6±1.4 years. Limb lengths
were as follows: common channel 76±7 cm, biliopancreatic
limb 79±14 cm, and alimentary (Roux) limb 604±99 cm.
The operation was performed laparoscopically in 95.2 % of
the cases. Thirty-day mortality was zero; major and minor
complication rate was 4.5 % and 10.4 %, respectively.
Average excess weight loss (EWL) was >74 % 3, 4, and
5 years after the operation and failure rate defined by an
EWL<50 % remained<6 %. Annually blood measurements
revealed a relatively low incidence rate of severe nutritional
deficiencies, but mild anaemia and hypoproteinemia were
frequently observed. Laparoscopic revision with a proxim-
alization of the lower anastomosis was required in 4 (1.1 %)
patients. Data indicate that our DVLRYGB leads to
excellent weight loss results. Furthermore, within the setting
of a structured multidisciplinary follow-up program, the
incidence of severe malnutrition states was relatively low.
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Introduction
Bariatric surgery currently represents the most effective
weight loss therapy for patients with severe obesity. Accord-
ing to international guidelines, bariatric surgery is indicated
in patients with a body mass index (BMI) of 40 kg/m2 or
higher as well as in patients with a BMI above 35 kg/m2 in
conjunction with obesity-associated co-morbidities such as
type 2 diabetes, hypertension, or obstructive sleep apnea
syndrome [1]. In such patients, bariatric surgery has been
shown to increase quality of life and to reduce obesity-
related co-morbidities as well as overall mortality [2–5].
The term “bariatric surgery” covers a broad range of
different surgical procedures that distinctly differ in their
effectiveness to reduced body weight [6]. Mechanical re-
striction of food intake and malabsorption of macronutrients
are traditionally believed to represent the principle mecha-
nisms by which bariatric operations reduce body weight.
Some bariatric procedures, however, additionally lead to an
altered secretion of gastrointestinal hormones which in turn
affect central nervous networks that regulate energy metab-
olism and eating behavior [7]. In particular, Roux-en Y
gastric bypass (RYGB) surgery, i.e. the currently most fre-
quently performed bariatric procedure [8], has consistently
been shown to enhance the postprandial release of several
satiety hormones such as glucagon-like peptide (GLP) 1 and
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polypeptide (P) YY [9]. While such hormonal effects of the
surgery enhance satiety, reduce hunger, and probably even
ameliorate the hedonic drive to consume palatable food
[10], some patients still have an inappropriately high caloric
intake that limits the extent of achieved weight loss or
causes body weight regain in the long run.
High rates of treatment failure, as defined by an excess
body weight loss (EWL) of less than 50 %, have been
reported in many RYGB cohort studies [11, 12]. For in-
stance, in the large cohort of Christou et al. [12] including
more than 1,000 patients the long-term failure rate was 20 %
in patients with a preoperative BMI between 40 and 49 kg/
m2 and 35 % in patients with a preoperative BMI between
50 and 60 kg/m2. In order to reduce failure rates, Sanchez-
Santos et al. [11] systematically varied the length of the
Roux, also called alimentary, limb according to the patient’s
preoperative BMI. By establishing a Roux limb length of
100 cm in patients with a BMI below 50 kg/m2 and a length
of 150 cm in patients of BMI above 50 kg/m2, they achieved
relatively low failure rates of 18.5 % and 12.5 %, respec-
tively, 5 years after the operation. Of note, the relevance of
the Roux limb length in regard of weight loss had been
demonstrated long before this study by Brolin et al. [13]
who found a greater weight loss after establishing a Roux
limb length of 150 cm compared with a Roux limb length of
75 to 100 cm. However, performing a similar systematic
variation in Roux limb length (150 cm in BMI>48 kg/m2
patients and 100 cm in BMI<48 kg/m2 patients), Suter et al.
reported on even higher failure rates, i.e. 40–50 % in BMI>
48 kg/m2 patients and 25 % in BMI<48 kg/m2, in a Swiss
cohort of severely obese patients [14].
In order to further improve weight loss outcomes, Brolin et
al. [15] performed a procedure called “distal RYGB” in
patients with a BMI above 50 kg/m2 and compared the effects
of this procedure with that of proximal RYGB operations
displaying a Roux limb length between 50 and 150 cm [15].
In their distal RYGB variant, the Roux limb was very long but
the common channel, i.e. the distance between the lower
anastomosis to the ileocolic junction, was only 75 cm. As
expected, results of the study clearly revealed a greater weight
loss after the distal than proximal RYGB surgery. However,
since the distal RYGB variant frequently also provoked severe
metabolic problems, in particular anaemia, the procedure did
not become widely accepted in the bariatric community. Sim-
ilar experience was made by Sugerman et al. when they
performed different distal RYGB variants in 27 patients who
had previously been failed to lose enough body weight upon a
proximal RYGBwith a Roux limb length of 45 cm [16]. In the
first 5 patients, a common channel of only 50 cm was estab-
lished resulting in such a very severe malnutrition that all
patients required an operative revision. In the subsequent 22
patients, a common channel of 150 cm was established but
patients still showed relatively high rates of severe
malnutrition. Of note, however, in both of these two distal
RYGB variants, the Roux limb length was only 145 cm allow-
ing the ingested food only a relatively short contact with the
gut resulting in a distinctly reduced absorption of nutritions.
Müller et al. [17] recently performed a non-randomized
study in which they compared the effects of distal vs.
proximal RYGB in a total of 50 patients with an average
BMI of about 45 kg/m2. While the authors did not report on
relevant nutritional problems, they could not detect any
differences in the amount of weight loss achieved after a
median follow-up period of 4 years between the two bari-
atric procedures. However, their distal RYGB variant dis-
played a common channel length between 100 and 150 cm
which presumably is too long to establish a significant
degree of malabsorption and thus, is unable to improve the
weight loss outcome. Also, this study was obviously under-
powered since the detection of a reduction of the failure rate
from 20 % to 15 % with a power of 0.8 requires a sample
size of more than 900 patients per group.
In clinical practice, bariatric surgeons are increasingly con-
fronted with a substantial number of patients who have un-
dergone RYGB surgery but are not satisfied with or even
frustrated about their long-term body weight loss result. In
such situations, secondary bariatric operations which establish
a stronger degree of malabsorption may be offered in order to
achieve a greater reduction of excess body weight. However,
classic malabsorptive procedures such as duodenal switch or
Scopinaro’s procedure, both of which establish a biliopancre-
atic diversion (BPD), also carry the risk of severe nutritional
deficiencies, in particular hypoproteinaemia, and chronic di-
arrhea [18]. Also, it must be considered that any secondary
operation puts the patient on an additional risk of perioperative
complications. Thus, every patient with an insufficient weight
loss after RYGB brings the question into mind whether
patients with an anticipated high risk of weight loss failure,
e.g. due to a very high preoperative BMI or a particularly
unfavorable eating behavior, should to be offered an alterna-
tive, putatively more effective procedure than a 150-cm Roux
limb length proximal RYGB as a first line bariatric operation.
Addressing this question in 2002, we established a novel
variant of distal RYGB as a primary bariatric procedure at
our institution for patients that were assumed to have a high
risk for insufficient weight loss after a proximal RYGB
operation. The principle idea was to establish a strong
malabsorption of nutritional fat by creating a relatively short
common channel but leaving a very long alimentary limb
for the transit of ingested foods that allows for a proper
absorption of micronutrients and proteins being digested by
proteases locally expressed by the small bowel mucosa.
Here we report up to 5-year follow-up results of the first
355 patients who have undergone this so called Distal Very
Long Roux-en Gastric Bypass (DVLRYGB) as a primary
bariatric procedure in our institution.
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Materials and Methods
Patients’ Selection
A total of 355 patients were selected for offering the
DVLRYGB as a primary bariatric procedure and gave written
informed consent to undergo the operation. Selection criteria
included a high BMI, unfavorable eating behavior character-
ized by a high intake of nutritional fat, and an assumed or self-
reported low level of cognitively controlled eating behavior.
Also, severe medical problems related to obesity such as type
2 diabetes or sleep apnea syndrome favored the offering of the
DVLRYGB. Medical conditions, eating behavior, and
psycho-social circumstances were carefully assessed by a
multidisciplinary team comprising internists, nutritionists,
psychologists, and the surgeon. However, the selection of
the patient did not rely on a clear-cutely defined algorithm
but rather reflected the overall clinical impression of the
patient’s individual situation. The final decision for offering
the distal RYGB variant was made by the chief bariatric
surgeon (MT) and intensively discussed with the patients.
Surgical Procedure
All operations were performed by MT. The operation was
performed laparoscopically whenever possible by using 6
ports of 12 mm (in the case of concurrent cholecytectomy,
an additional port of 7 mm was used). Like in proximal
RYGB procedures, the largest part of the stomach was
transected thereby creating a small gastric pouch of approx-
imately 20–30 ml which was anastomized to the proximal
jejunum. The pouch-jejunal anastomosis was standardized
by using a 25-mm-round stabler (ECS 25 mm; Ethicon
Endo-SurgeryTM). The biliopancreatic limb was side-to-
side anatomized to the ileum 60 and 100 cm proximal from
the ileocolic junction thereby establishing the common
channel. The exact length of an individual’s common chan-
nel was designed to count 10 % of the total length of the
small bowel as measured in 5 cm intervals from the ileocolic
junction to the ligament of Treitz. However, the minimal
common channel length was set to be at least 60 cm. The
length to the biliopancreatic limb, as measured from the
ligament of Treitz to the lower anastomosis, was 60 to
100 cm depending on the individual anatomical situation.
Thus, our DVLRYGB, in contrast to classical BPD proce-
dures or the distal RYGB procedures previously performed
by Sugerman [16], displays a very long alimentary limb for
the passage of food and absorption of nutritions.
Preoperative Preparation
Before the surgery, all patients were carefully informed on
how to adjust their eating behavior to the postoperative
situation. This was done by providing at least two structured
nutritional counseling sessions. Each session lasted 45 to
60 min and mainly focused on adequate protein intake and
the avoidance of the consumption of foods containing high
amounts of fat and simple carbohydrates after the surgery.
Also, special cooking and shopping courses were offered to
the patients, but participation in such courses was not a
prerequisite for undergoing the surgery.
All patients were advised to lose some weight prior the
operation but they did not have to follow a particular diet.
Patients were also advised to do some exercise before the
surgery in order to improve their physical condition. From
July 2005 on, we offered the patients the participation in a
special exercise program taking place within our Interdisci-
plinary Obesity Center (IOC). Medical conditions were im-
proved as much as possible before the operation, e.g. by
establishing an optimal blood pressure, glycemic, and lipid
control by the implementation of respective pharmacological
therapies or by establishing positive airways pressure ventila-
tion in patients with newly diagnosed sleep apnea syndrome.
Follow-up Program
After the surgery, all patients were included in a structured
multidisciplinary follow-up program taking place on an out-
patients basis in the IOC. This included repeated consulta-
tions with the surgeon or internist 1, 3, 6, 9, 12, 18, and
24 month after the surgery. From the third postoperative
year on the follow-up, intervals were extended to 12 months
provided a stable clinical and psychosocial situation. In the
case of any medical problem, additional consultations were
offered. Apart from the consultations with the doctor, all
patients had at least three nutritional counseling sessions
within the first year after the surgery. Additional sessions
with the nutritionist as well as psychological support by
trained psychotherapists were offered whenever necessary
during the follow-up.
Metabolic and nutritional blood parameters were measured
before and at least once per year after the operation. A stan-
dardized supplementation regime (see below) was prescribed
to all patients with individual adjustments according actual
results of nutritional blood measurements. Compliance with
the supplementation regime was checked by the doctors at
every visit of the patients in the ICO and patients were
motivated to improve their compliance whenever necessary.
Supplementation Regime
To prevent nutritional deficiencies, a standard supplementa-
tion therapy regimen including 100 mg iron/day p.o. (iron
(II) fumarate or iron(III) hydroxid-polymaltose both without
additional vitamin C) or 500 mg ferric carboxymaltose i.v.
every 6 to 18 months, 1.5 g calcium/day p.o. (calcium
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carbonate, since calcium citrate is not available in Switzer-
land), 1,500 IU vitamin D3/day p.o., one multivitamin pill
containing trace elements per day, and one tablet of vitamin
B-complex (twice a week) was prescribed to the patient. In
addition, 1,000 mycro g vit B12 was injected i.m. every
3 months. In the case of zinc deficiency, 30 mg/day p.o.
was prescribed. In the case of vitamin D3 deficiency, addi-
tional i.m. injections of 300,000 IU were given every
3 months. Dose adjustments were made whenever necessary
upon respective values of blood measurements.
Body Weight Assessment
Body height and weight were measured in all subjects while
they were wearing light clothes but no shoes. The percent
body weight loss (%BWL) was calculated by the formula
preoperative weight kgð Þcurrent weightð Þ preoperative=ð½
weightÞ100 and percent excess weight loss (%EWL) was
calculated by the formula preoperative weight currentð½
weightÞ preoperativeweightð= height cmð Þ  100ð ÞÞ  100
and percent excess BMI loss (%EBL) was calculated
by the formula preoperative BMI  current BMIð Þ =ð½
preoperative BMI 25ð ÞÞ100.
Metabolic and Nutritional Blood Parameters
In all patients, blood samples were drawn in the morn-
ing (8:00–11:00) after an overnight fast. Metabolic
parameters were classified according to following cut-
off values: glucose >126 mg/dl for patients being in the
diabetic range and >100 mg/dl for patients being in the
impaired fasting glucose or diabetic range. Dyslipidemia
was defined as triglycerides >150 mg/dl, total cholester-
ol >193.0 mg/dl, LDL cholesterol >100 mg/dl, HDL
cholesterol <46.0 mg/dl for women and <38.7 mg/dl
for men or total/HDL cholesterol >5.0. However, it
should be noted that no reliable data on the use of
glucose or lipid lowering drugs were available and thus,
not analysed.
Nutritional deficiencies were defined as follows: serum
total protein <63.0 g/l; serum albumin <34.0, <30.0, or
<25 g/l; serum vitamin B12 <180.0 ng/l; serum folate
<2.0 μg/l; serum 25-OH vitamin D3 <10.0 ng/ml; serum
calcium <8.0 mg/dl; serum zinc <720.0 μg/l; serum
ferritin <10.0 μg/l for women and <25.0 μg/l for men;
hemoglobin <120 g/l and <100 g/l for women and <140 g/l
and <120 gl/l for men. A serum iPTH level >65 ng/l indicated
hyperparathyroidism.
Statistical Analysis
This study represents a retrospective analysis of a prospec-
tively maintained database which was approved by the local
ethic committee. Data are reported as mean±SD and per-
centages of the total number of included patients in the
study unless otherwise indicated. Data were analysed by
using SPSS 12.1 for Windows (SPSS Inc., Chicago, IL).
Changes in metabolic and nutritional blood parameters over
time were assessed by linear mixed models. For pair-wise
comparisons, Student’s t tests were used. A P value of less
than 0.05 was considered significant.
Results
Patient’s Characteristics and Follow-up Rates
Between February 2002 and October 2010, a total of 355
severely obese patients underwent a DVLRYGB operation
as a primary bariatric procedure in our institution. The
preoperative characteristics of these patients are provided
in Table 1. Average follow-up time was 1.6±1.4 years and
the overall follow-up rate was 98.9 %. Table 2 shows the
number of patients and the follow-up rates over the 5-year
course of the study. Although the follow-up rates decreased
over time, they were still higher than 91 % 5 years after the
surgery.
Characteristics of the Operation and Complication Rates
The characteristics of the operation are summarized in Table 3.
The majority of operations (>95 %) could be performed
Table 1 Preoperative patients’ characteristics
N 355
Age (years) 41.4±10.8
Women (%) 72.4
Height (cm) 165.4±11.1
Weight (kg) 131.4±22.9
BMI (kg/m2) 48.5±11.5
BMI 35–<40 kg/m2 9.3 % (n033)
BMI 40–<50 kg/m2 61.4 % (n0218)
BMI 50–<60 kg/m2 22.8 % (n081)
BMI ≥60 kg/m2 6.5 % (n023)
Diagnosis of
Diabetes 18.6 % (n066)
Arterial hypertension 49.3 % (n0175)
Dyslipidemia 27.3 % (n097)
Obstructive sleep apnea syndrome 19.4 % (n069)
Depression 17.5 % (n062)
Other psychiatric disordersa 7.3 % (n026)
Data are mean ± SD or percentages (number) of patients
BMI body mass index
a Other than depression
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laparoscopically. Limb length varied from patient to patient
depending on the individual’s total bowel length which was
on average impressively long, i.e. about 760 cm. Mortality
upon the DVLRYGB surgery was zero, but one patient died
during the follow-up, i.e. 4.3 years after the surgery, upon
progressive pulmonary cancer. Major surgical complications
are summarized in Table 4 and minor surgical complications
in Table 5. General complications occurred in 11 patients
(3.1 %), one (0.3 %) cardiac, and 10 (2.8 %) pulmonary (3
(0.9 %) peripheral pulmonary embolism and 6 (1.7 %) pneu-
monia) complication.
During the follow-up, a proximalization of the lower
anastomosis was required in 4 (1.1 %) patients, in two cases
due to severe hypoproteinemia resulting from malcompli-
ance with nutritional recommendations (case 1 and 2), in
one case due to persistent cholegenic severe diarrhea (case
3), and in another case due to persistent chylascites of
unknown origin (case 4). All of these revisions could be
performed laparoscopically without any complications and
the preexisting symptomatology remitted in all cases postop-
eratively. The time interval between the initial DVLRYGB
Table 2 Eligible and available patients during the follow-up
Year after
surgery
Eligible patients
(% of total)
Available patients
(% of eligible)
0 355 (100) 355 (100)
1 213 (60.0) 213 (100)
2 171 (48.2) 168 (98.3)
3 93 (26.2) 89 (95.7)
4 40 (11.3) 37 (92.5)
5 12 (3.4) 11 (91.7)
Table 3 Operations’ characteristics
Surgical technique
Laparoscopic n0338 (95.2 %)
Open n017 (4.8 %)
Conversiona n012 (3.4 %)
Operation time
Overall operation time (min) 139.8±42.1
Laparoscopic operation time (min) 139.1±41.9
Open operation time (min) 162.9±48.0
Limb length
Total small bowel length (cm)b 759±101
Alimentary limb length (cm)c 604±99
Biliopancreatic limb length (cm)d 78.6±14.1
Common channel length (cm) 76.1±7.2
Data are mean±SD or number (percentages) of patients
a Started laparoscopic with intra operative conversion to open surgery
bMeasured from the ileocecal junction to the ligament of Treitz
cMeasured from the upper anastomosis to the lower anastomosis
dMeasured from the ligament of Treitz to the lower anastomosis
Table 4 Major surgical complications
Number of patients with major complications n016 (4.5 %)
Patients with one major complications n014 (3.9 %)
Patients with two major complications n02 (0.6 %)
Onset of major complications
Early (<30 days after surgery) n010 (2.8 %)
Late (>30 days after surgery) n010 (2.8 %)
Specific major complications
Remnant stomach n01 (0.3 %)
Gastric fistula, blind n02 (0.6 %)
Gastrojejunostomy leak n02 (0.6 %)
Stapleline rupture (pouch) n03 (0.8 %)
Bleeding (intraabdominal) n02 (0.6 %)
Bowel obstruction n04 (1.1 %)
Small bowel (adhaesion) n01 (0.3 %)
Lower anastomosis n01 (0.3 %)
Internal hernia n02 (0.6 %)
Perforation (stomach) n02 (0.6 %)
Treatment
Operative revision n017 (4.8 %)
Laparoscopic revision n09 (2.5 %)
Conservative treatment n02 (0.6 %)
Data are number (percentages) of patients
Table 5 Minor surgical complications
Total number of minor complications n037 (10.4 %)
Onset of minor complications
Early (<30 days after surgery) n011 (3.1 %)
Late (>30 days after surgery) n026 (7.3 %)
Specific minor complications
Cutis/subcutis infection n04 (1.1 %)
Bridge/adhaesiolysis/subileus n06 (1.7 %)
Blindloop (jejenunoileostomy) n01 (0.3 %)
Hematoma n02 (0.6 %)
Bleeding (intraluminal) n08 (2.3 %)
Gastrojejenunostomy n05 (1.4 %)
Jejunoileostomy n03 (0.8 %)
Internal hernia n01 (0.3 %)
Ulcus gastrojejunostomy n07 (2.0 %)
Stenosis (gastrojejunostomy) n08 (2.3 %)
Hiatal hernia n02 (0.6 %)
Treatment
Operative revision n014 (3.9 %)
Laparoscopic revision n010 (2.8 %)
Conservative treatment n024 (6.8 %)
Data are percentages (number) of patients
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operation and the revisional proximalization was in all case
less than 1 year (case 1, 4 months; case 2, 9 months; case 3,
6 months; case 4, 10 months). The length of the common
channel and the Roux (alimentary) limb before and after the
proximalization were as follows: Case 1: before 70 and
505 cm, and after 130 and 445 cm, respectively. Case 2: before
70 and 560 cm, and after 480 and 150 cm, respectively. Case
3: before 80 and 630 cm, and after 560 and 150 cm, respec-
tively. Case 4: before 75 and 505 cm, and after 110 and
470 cm, respectively.
Body Weight Course
The course of body weight, BMI, %BWL, %EWL, and
%EBL as well as the failure rates during the 5-year
follow-up are listed in Table 6 and illustrated in Fig. 1. In
most cases (85.1 %), body weight continued to decrease
during the second postoperative year reaching an overall
failure rate, defined as an EWL of less than 50 %, of
3.4 % 3 years after the operation. During the following
follow-up years, the failure rate remained below 6 %.
Metabolic and Nutritional Blood Parameters
Table 7 summarizes levels of metabolic blood parameters
before and after the surgery. Overall, there was a marked
improvement of glucose and lipid levels after the surgery,
with the number of patients showing abnormal glucose or
lipid levels being distinctly reduced.
The course of nutritional blood parameters is shown in
Table 8. Mean serum protein as well as albumin levels
decreased and the number of hypoproteinemic and hypoal-
buminemic patients increased after the surgery. Severe
hypoproteinemia or hypoalbuminemia, however, was rarely
Table 6 Changes in body weight parameters after surgery
Time Weight (kg) BMI (kg/m2) %BWL % EWL % EBL Failure ratea
Pre OP 131.4±22.9 48.5±11.5 – – –
1-year Follow-up 87.6±18.1 32.0±6.8 34.2±8.6 69.7±18.3 73.8±19.7 9.4 % (n020)
2-year Follow-up 82.3±16.1 30.0±6.2 39.0±8.4 78.4±17.2 82.6±18.4 5.4 % (n09)
3-year Follow-up 84.5±16.1 29.9±4.6 38.7±8.0 77.6±17.0 81.2±18.0 3.4 % (n03)
4-year Follow-up 87.3±14.9 31.1±4.3 39.4±8.9 74.6±15.4 77.6±15.9 5.4 % (n02)
5-year Follow-up 92.9±19.2 32.2±5.7 41.9±8.5 75.9±14.3 78.2±15.2 0 % (n00)
Data are mean±SD or percentages (number) of patients
BMI body mass index, %BWL percentage body weight loss, %EWL percentage excess weight loss, %EBL percentage excess BMI loss
a Defined as a EWL of less than 50 %
Fig. 1 Mean±SD weight (a),
BMI (b), %EWL (c), and
%EBL (d) course after the
novel distal very long Roux-en
Y gastric bypass variant
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observed and in most case recovered after a temporary
supplementation with protein powder. However, 4 (1.1 %)
patients had to be hospitalized for temporary tube feeding
and, as stated above, 2 (0.6 %) patients even required
surgical revision with proximalization of the lower anasto-
mosis due to refractory severe hypoproteinemia. After this
revision surgery, protein levels rapidly recovered and
remained stable thereafter.
In both men and women, haemoglobin levels decreased
and the prevalence of anaemia distinctly increased after the
operation. However, the degree of anaemia was generally
moderate and did not provoke any clinical consequences. As
expected, men showed higher serum ferritin levels than
women before the surgery (P<0.001). After the operation,
ferritin levels increased in women while they decreased in
men. The prevalence of hypoferritinemia appeared to be
increased during the first two to three postoperative years
in both sexes but was reduced thereafter. Mean serum zinc
levels remained essentially unchanged after the operation
but number of patients showing a below cut-off serum zinc
concentration was found to be increased 1 year after the
operation.
Serum levels of folic acid, vitamin B12, and 25-OH
vitamin D3 increased after operation and deficiency rates
were generally lower than before the operation. Mean serum
PTH levels were reduced 1 year after the operation but
tended to increase thereafter. Also, the number of patients
showing a secondary hyperparathyreoidism was reduced
1 year after the operation as compared with the preoperative
state, but slightly increased thereafter. Serum calcium levels
slightly decreased over time but stayed well within the
reference range.
Discussion
In the present study, we analysed complication rates and the
course of body weight as well as of metabolic and nutrition-
al blood parameters in the first 355 patients who have
undergone our novel DVLRYGB as a primary bariatric
Table 7 Metabolic parameters before as well as up to five years after distal very long Roux-en Y gastric bypass
Preoperative 1 year after
DVLRYGB
2 years after
DVLRYGB
3 years after
DVLRYGB
4 years after
DVLRYGB
5 years after
DVLRYGB
P value
overall
n0355 n0213 n0168 n089 n037 n011
Glucose
Mean±SD, mg/dl 108.1±34.2 84.7±16.2*** 84.7±14.4*** 88.3±21.6*** 93.7±27.0** 84.7±9.0** <0.001
Elevated levels
(>126 mg/dl; %)
15.9 2.8*** 2.3*** 2.3 7.4 0*** <0.001
Elevated levels
(>100 mg/dl; %)
42.6 6.1*** 7.0*** 6.3* 14.8*** 0*** <0.001
Triglycerides
Mean±SD, mg/dl 166.6±96.5 96.5±43.5*** 105.2±52.6*** 96.5±52.6*** 114.0±78.9*** 87.7±43.9*** 0.024
Elevated levels
(>150 mg/dl; %)
51.1 11.7*** 13.1*** 10.5*** 20.0** 11.1** <0.001
Total cholesterol
Mean±SD, mg/dl 197.2±42.5 139.2±220.4*** 131.5±27.1*** 131.5±30.9*** 135.4±23.2*** 135.4±23.2*** <0.001
Elevated levels
(>193.0 mg/dl; %)
51.5 3.1*** 4.7*** 2.6*** 4.0 4.0 <0.001
LDL cholesterol
Mean±SD, mg/dl 116.0±34.8 54.1±19.3*** 58.0±19.3*** 61.9±19.3*** 65.7±34.8*** 69.6±30.9*** <0.001
Elevated levels
(>100.0 mg/dl; %)
70.1 4.1*** 3.9*** 8.1*** 4.0*** 22.2** <0.001
HDL cholesterol
Mean±SD, mg/dl 46.4±11.6 50.3±15.5 54.1±15.5** 54.1±15.5** 54.1±19.3 58.0±15.5 <0.001
Low valuesa (%) 41.5 38.4 27.1** 29.7* 32.0 11.1* 0.015
Cholesterol/HDL cholesterol
Mean±SD 4.3±1.2 2.6±0.7*** 2.6±0.7*** 2.6±0.8*** 2.9±1.1*** 2.6±0.8*** <0.001
Elevated levels (>5.0; %) 27.4 2.2*** 0*** 1.3*** 4.0*** 0*** <0.001
Data are mean±SD or percentages of patients
a HDL <46.0 mg/dl for women and <38.7 mg/dl for men
*P<0.05; **P<0.01; ***P<0.001 vs preoperative data
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Table 8 Nutritive parameters before as well as up to 5 years after distal very long gastric bypass
Preoperative 1 year after
DVLRYGB
2 years after
DVLRYGB
3 years after
DVLRYGB
4 years after
DVLRYGB
5 years after
DVLRYGB
P value
overall
n0355 n0213 n0168 n089 n037 n011
Protein
Mean±SD, g/l 69.8±8.2 64.3±5.1*** 64.0±5.1*** 64.0±5.5*** 63.5±6.0*** 60.3±9.0** <0.001
Deficiency (<63.0 g/l) rate (%) 2.7 36.7*** 35.8*** 29.9*** 40.7** 55.6 <0.001
Albumin
Mean±SD, g/l 40.9±4.3 38.9±4.9*** 39.8±4.2* 39.8±4.2* 38.9±11.9* 31.7±11.9* <0.001
Deficiency (<34.0 g/l) rate (%) 4.0 13.3 6.8 7.7 4.2 22.2 0.28
Deficiency (<30.0 g/l) rate (%) 1.2 4.0* 3.0 3.9 0** 11.1 0.016
Deficiency (<25.0 g/l) rate (%) 0.3 1.3 0.8 0 0 11.1 0.18
Vitamin B12
Mean±SD, ng/l 271±114 318±249** 347±300** 317±232 474±396** 424±218* 0.004
Deficiency (<180 ng/l) rate (%) 18.5 16.6 21.2 28.0 20.0 11.1 0.12
Folic acid
Mean±SD, μg/l 5.4±3.0 12.8±6.3*** 13.6±9.9*** 13.3±5.5*** 13.3±4.7*** 12.9±6.9** <0.001
Deficiency (<2.0 μg/l) rate (%) 2.2 0.5 0.8 0 0 0 0.17
25(OH)Vit D3
Mean±SD, ng/ml 20.2±14.7 30.7±14.4*** 28.8±14.4*** 29.7±14.4*** 27.1±11.3** 33.2±8.7** <0.001
Deficiency (<10.0 ng/ml) rate (%) 18.4 7.2*** 5.5*** 4.0*** 0*** 0*** <0.001
Parathormone
Mean±SD, ng/l 55.7±29.8 45.2±21.4*** 56.4±40.4 56.3±25.5 60.9±27.3 61.2±20.8 <0.001
Hyperparathyroidism (>65 ng/l) 24.9 14.1** 24.8 29.7 50.0* 33.3 0.003
Total calcium
Mean±SD, mg/dl 9.3±0.04 9.0±0.04 9.8±0.04 9.0±0.04 9.0±0.08 8.9±0.12 <0.001
Deficiency (<8.0 mg/dl) rate (%) 0.7 0.4 0 0 0 0 0.556
Albumin adjusted calcium
Mean±SD, mmol/l 2.28±0.01 2.26±0.01 2.23±0.01 2.24±0.01 2.28±0.002 2.31±0.03 0.017
Zinc
Mean±SD, μg/l 908.6±196.1 849.8±222.3 941.3±353.0 960.9±261.5 928.3±163.4 895.7±183.0 0.05
Deficiency (<720.0 μg/l) rate (%) 14.7 32.9*** 19.9 6.7* 12.0 33.3 <0.001
Ferritin women
Mean±SD, μg/l 62±52 101±83*** 89±92** 102±172 84±107 191±111* <0.001
Deficiency (<10.0 μg/l) rate (%) 5.2 3.1 2.3 10.0 6.3 0*** <0.001
Ferritin men
Mean±SD, μg/l 174±128 139±118 104±72*** 100±122** 124±119 161±165 <0.001
Deficiency (<25.0 μg/l) rate (%) 2.3 9.8 6.8 7.7 0 0 0.01
Hemoglobin women
Mean±SD, g/l 140±20 130±11*** 132±30* 127±21*** 120±12*** 126±11** <0.001
Deficiency (<120 g/l) rate (%) 2.5 17.3*** 21.6*** 20.0** 57.9*** 42.9 <0.001
Deficiency (<100 g/l) rate (%) 0.4 0.6 0 2.0 5.3 0 0.16
Hemoglobin men
Mean±SD, g/l 151±19 140±21** 136±23*** 139±14*** 141±21 129±35 0.018
Deficiency (<140 g/l) rate (%) 14.3 39.7** 46.7*** 40.7* 44.4 50.0 0.034
Deficiency (<120 g/l) rate (%) 1.1 6.4 4.4 7.4 11.1 50.0 0.98
Data are mean±SD or percentages of patients
DBG distal gastric bypass
*P<0.05; **P<0.01; ***P<0.001 vs. preoperative data
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procedure in our institution. While the average follow-up
time was still relatively short (i.e. 1.6 years), the number of
patients displaying a follow-up of 4–5 years was still suffi-
cient to obtain reliable midterm results. Importantly, the
follow-up rate in our study was extraordinary high, thereby
excluding a strong biasing influence of follow-up drop outs.
Overall surgical and general complication rates after our
DVLRYGB appear to be comparable with those reported
after proximal RYGB surgery [19–24]. Even more impor-
tant, in our series the occurrence of severe nutritional prob-
lems was relatively low compared with nutritional
complication rates previously reported after different distal
RYGB variants [15, 16]. Weight loss results characterized
by an EWL of more than 74 % and a failure rate of less than
6 % over 5 years as well as the marked improvement of
metabolic blood parameters are obviously excellent and
underscore the effectiveness of the operation.
Nutritional problems were relatively mild in most cases
and seldom required medical interventions. However, it is
important to note that we observed some alterations in
nutritional blood parameters that definitively call for atten-
tion. In particular, a substantial number of patients showed
an, albeit mild, anemia, and hypoprotein/albuminemia.
While such a state may not provoke any adverse symptoms,
its long-term consequences remain to be explored. Further-
more, it needs to be emphasized that results in our study
were obtained within a setting of a structured multidisciplin-
ary follow-up program which included a standardized sup-
plementation regime. It appears questionable whether
similar results can be obtained in less intensive follow-up
settings. However, our study might be regarded as a “proof
of principle” in the view that within an optimal follow-up
program excellent weight loss results can be achieved by
our DVLRYGB without provoking severe nutritional
problems.
As expected, metabolic variables such as fasting glucose
and lipid levels greatly improved after the DVLRYGB sur-
gery. However, these data need to be interpreted with cau-
tion since we did not systematically monitor the medication
of the patients. While this shortcoming could certainly have
biased our results, it should also be mentioned that in our
experience most patients rather reduce than increase the
intake of glucose or lipids lowering drugs after DVLRYGB.
The relevance of the amount of weight loss achieved by
bariatric operations has been taken into question by several
bariatric surgeons since even suboptimal weight loss appear
to be associated with an improvement in quality of life [4,
14]. On the hand, however, analyses of carefully assessed
psychometric data in the Swedish Obese Subjects (SOS)
study clearly indicated that the improvement in most psy-
chometric parameters correlate with the amount of achieved
lost weight in the long-term [25]. Unfortunately, we did not
systematically assess quality of life in our patients so that in
conjunction with the lack of an adequate control group it
remains unknown whether our excellent weight loss results
were associated with an even greater improvement in quality
of life.
Patient selection in our study did not follow a clear-cutely
predefined algorithm which clearly represents a weakness of
our study. The decision to offer the novel DVLRYGB to a
patient was mainly based on results of a multidisciplinary
evaluation, which took into account the degree of obesity,
comorbidities, eating behavior, and the psychosocial situation
of the patients. Obviously, such a selection regime is highly
vulnerable to personal experiences and attitudes which could
have biased our results. While our approach to allocate
patients to distinct bariatric procedures likely represents the
clinical practice performed in most bariatric institutions, i.e.
decisions being mainly based on personal experiences, there is
clearly a great need to establish and validate objective alloca-
tion algorithms. However, the fact that strong and reliable
predictors for the outcome after distinct bariatric procedures
have not been identified yet makes it very difficult to set up
evidence-based algorithm at this point.
In conclusion, our study demonstrates that excellent
weight loss results in conjunction with acceptable risks can
be achieved with the DVLRYGB. However, we also want to
emphasize that in our view a structured follow-up program
carried out by a multidisciplinary team represents a prereq-
uisite for offering such an operation to severely obese
patients. Also, a longer follow-up period will be required
to assess the long-term efficacy and safety of the
DVLRYGB procedure.
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